Intensity Therapeutics公司公布的Invincible-4初步研究数据揭示显著疗效差异：在接受其核心候选药物INT230-6与标准疗法联合治疗的患者组中，病理完全缓解率高达71.4%，而仅接受标准疗法对照组的缓解率则为33%。这一数据凸显了INT230-6在联合用药方案中的巨大治疗潜力。
Intensity Therapeutics公司公布的Invincible-4初步研究数据揭示显著疗效差异：在接受其核心候选药物INT230-6与标准疗法联合治疗的患者组中，病理完全缓解率高达71.4%，而仅接受标准疗法对照组的缓解率则为33%。这一数据凸显了INT230-6在联合用药方案中的巨大治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.